Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05536804 · ClinicalTrials.gov registry record · Phase 2

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

A Phase 2 study of Obesity and Type 2 Diabetes, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 2
Development phase
140
Enrollment target
20
Study locations

NCT05536804 is a Phase 2 study of Obesity and Type 2 Diabetes that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 140 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05536804, a Phase 2 study of Obesity and Type 2 Diabetes, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
140 participants
Enrollment target
20
Study locations

Study Summary

We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.

Conditions Studied

Obesity Type 2 Diabetes Overweight Chronic Kidney Disease T2D

Interventions

  • DRUG Placebo
  • DRUG Tirzepatide

Study Locations (20)

Other

  • Klinik Landstraße - Vienna
  • Zentrum für klinische Studien Dr Hanusch Gmbh - Vienna
  • Klinik Hietzing - Vienna
  • LMC Clinical Research Inc. (Barrie) - Barrie
  • LMC Clinical Research Inc. (Thornhill) - Concord
  • Centre intégré universitaire de santé et de services sociaux de l'Estrie Centre Hospitalier Universitaire -T - Sherbrooke
  • Toronto General Hospital - Toronto
  • Fadia El Boreky Medicine - Waterloo
  • Aarhus Universitetshospital, Skejby - Aarhus
  • Centro de Investigación y Gastroenterología - Cuauhtémoc

Indiana

  • American Health Network of Indiana, LLC - Avon - Avon
  • American Health Network of Indiana, LLC - Greenfield - Greenfield
  • Indiana University Health University Hospital - Indianapolis
  • American Health Network of Indiana, LLC - Muncie - Muncie

Colorado

  • University of Colorado Anschutz Medical Campus - Aurora
  • Kidney Associates of Colorado - Denver

Washington

  • University of Washington Medical Center - Montlake - Seattle
  • Providence Medical Research Center - Spokane - Spokane

California

  • Valley Clinical Trials, Inc. - Northridge

Michigan

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division - Troy

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2023-02-08
Est. Completion 2026-10
Phase Phase 2

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05536804

The ClinicalTrials.gov registry entry for NCT05536804 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05536804 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Indiana, Colorado.

Frequently Asked Questions

What is clinical trial NCT05536804 about?

NCT05536804 is a clinical study titled "A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes". We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.

What is the current status of trial NCT05536804?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2023-02-08. Estimated completion is 2026-10.

What conditions does trial NCT05536804 study?

This clinical trial studies the following conditions: Obesity, Type 2 Diabetes, Overweight, Chronic Kidney Disease, T2D.

What interventions are being tested in trial NCT05536804?

The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).

Who is sponsoring clinical trial NCT05536804?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05536804 being conducted?

This trial has 20 study locations across California, Colorado, Indiana, Michigan, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Type 2 Diabetes

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.